Skip to Content

Fidelity Advisor Biotechnology I FBTIX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 30.62  /  −0.16 %
  • Total Assets 1.8 Bil
  • Adj. Expense Ratio
    0.740%
  • Expense Ratio 0.740%
  • Distribution Fee Level Below Average
  • Share Class Type Institutional
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment
  • Status Open
  • TTM Yield 1.20%
  • Turnover 78%

USD | NAV as of Apr 19, 2024 | 1-Day Return as of Apr 19, 2024, 10:13 PM GMT+0

Morningstar’s Analysis FBTIX

Will FBTIX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Fidelity Advisor Biotechnology I’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTIX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 62.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

24.05 427.7 Mil
Healthcare

Amgen Inc

9.25 164.6 Mil
Healthcare

Regeneron Pharmaceuticals Inc

7.98 141.8 Mil
Healthcare

Ascendis Pharma A/S ADR

3.95 70.2 Mil
Healthcare

Alnylam Pharmaceuticals Inc

3.41 60.6 Mil
Healthcare

Cytokinetics Inc

3.27 58.2 Mil
Healthcare

Viking Therapeutics Inc

3.07 54.6 Mil
Healthcare

Gilead Sciences Inc

3.01 53.6 Mil
Healthcare

Vaxcyte Inc Ordinary Shares

2.49 44.2 Mil
Healthcare

argenx SE ADR

2.24 39.9 Mil
Healthcare